Education
About Us
Working with TipRanks
Follow Us
BetterLife Pharma (BETRF)
OTHER OTC:BETRF
BETRF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.05 - $0.13
Previous CloseN/A
Volume32.97K
Average Volume (3M)26.90K
Market Cap
$8.18M
Enterprise Value$17.40M
Total Cash (Recent Filing)$19.00K
Total Debt (Recent Filing)$1.30M
Price to Earnings (P/E)―
Beta-0.30
Next Earnings
Dec 19, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding151,838,730
10 Day Avg. Volume61,474
30 Day Avg. Volume26,899
Financial Highlights & Ratios
PEG Ratio-0.60
Price to Book (P/B)-1.51
Price to Sales (P/S)0.00
P/FCF Ratio-7.96
Enterprise Value/Market Cap2.13
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-12.04
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
BetterLife Pharma News
BETRF FAQ
What was BetterLife Pharma’s price range in the past 12 months?
BetterLife Pharma lowest stock price was $0.05 and its highest was $0.13 in the past 12 months.
What is BetterLife Pharma’s market cap?
BetterLife Pharma’s market cap is $8.18M.
When is BetterLife Pharma’s upcoming earnings report date?
BetterLife Pharma’s upcoming earnings report date is Dec 19, 2025 which is in 80 days.
How were BetterLife Pharma’s earnings last quarter?
BetterLife Pharma released its earnings results on Sep 26, 2025. The company reported -$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.002.
Is BetterLife Pharma overvalued?
According to Wall Street analysts BetterLife Pharma’s price is currently Overvalued.
Does BetterLife Pharma pay dividends?
BetterLife Pharma does not currently pay dividends.
What is BetterLife Pharma’s EPS estimate?
BetterLife Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BetterLife Pharma have?
BetterLife Pharma has 151,838,730 shares outstanding.
What happened to BetterLife Pharma’s price movement after its last earnings report?
BetterLife Pharma reported an EPS of -$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of BetterLife Pharma?
Currently, no hedge funds are holding shares in BETRF
Company Description
BetterLife Pharma
BetterLife Pharma Inc., a biotechnology company, engages in the development and commercialization of compounds for the treatment of neurological disorders in Canada and internationally. It is involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections. The company's pipeline products include BETR-001 for the treatment of major depressive disorder, treatment resistance depression, cluster headaches, and post-traumatic stress disorder; and BETR-002 to treat benzodiazepine dependency, anxiety, and spasticity. It is also developing MM-003 for treatment of COVID-19 and other respiratory viral infections; MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia; and AP-002 for the treatment of cancer. BetterLife Pharma Inc. has a research agreement with the University of California San Diego for preclinical behavioral pharmacology studies of TD-0148A, a lysergic acid diethylamide derivative solution. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.
Technical Analysis
Ownership Overview
31.66% Insiders
<0.01% Other Institutional Investors
68.33% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---